{"title":"Bivalirudin: risks associated with incorrect dose","public_updated_at":"2014-12-11T14:24:31Z","details":{"metadata":{"therapeutic_area":["cardiovascular-disease-lipidology"],"first_published_at":"2008-01-01T00:00:00Z","bulk_published":true,"document_type":"drug_safety_update"},"change_history":[],"body":[{"content_type":"text/html","content":"<p>Article date: January 2008</p>\n\n<p>Bivalirudin (Angiox▼) is a direct thrombin inhibitor that is approved for use as an anticoagulant in patients who are undergoing percutaneous coronary intervention (PCI). The approved dose for this indication is a 0·75-mg/kg bolus followed immediately by a 1·75-mg/kg/h infusion for the duration of the intervention.</p>\n\n<p>About 35% of patients entered into a European registry study (enrolled from various countries, but not the UK) received a single bolus or double bolus of bivalirudin without the required maintenance infusion. Most affected patients were recruited in Germany. These non-approved regimens resulted in substantial underdosing and were associated with an increased incidence of major adverse cardiac events (MACE), including cardiac death, myocardial infarction, and urgent revascularisation.</p>\n\n<div class=\"call-to-action\">\n<p>Advice for healthcare professionals explains:  </p>\n\n<ul>\n  <li>the approved dosing regimen for bivalirudin should be used in PCI. Use of a maintenance infusion after an initial bolus is necessary to ensure adequate anticoagulation during PCI.</li>\n</ul>\n</div>\n\n<p><a rel=\"external\" href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON2032914\">Letter sent to healthcare professionals in October 2007</a></p>\n\n<p><a rel=\"external\" href=\"http://www.medicines.org.uk/EMC/medicine/16741/SPC/Angiox+250mg+powder+for+concentrate+for+solution+for+injection+or+infusion/\">summary of product characteristics for Angiox▼</a></p>\n\n<p>Article citation: Drug Safety Update Jan 2008; Vol 1 Issue 6: 7</p>\n"},{"content_type":"text/govspeak","content":"Article date: January 2008\r\n\r\nBivalirudin (Angiox▼) is a direct thrombin inhibitor that is approved for use as an anticoagulant in patients who are undergoing percutaneous coronary intervention (PCI). The approved dose for this indication is a 0·75-mg/kg bolus followed immediately by a 1·75-mg/kg/h infusion for the duration of the intervention.\r\n\r\nAbout 35% of patients entered into a European registry study (enrolled from various countries, but not the UK) received a single bolus or double bolus of bivalirudin without the required maintenance infusion. Most affected patients were recruited in Germany. These non-approved regimens resulted in substantial underdosing and were associated with an increased incidence of major adverse cardiac events (MACE), including cardiac death, myocardial infarction, and urgent revascularisation.\r\n\r\n$CTA\r\nAdvice for healthcare professionals explains:  \r\n  \r\n* the approved dosing regimen for bivalirudin should be used in PCI. Use of a maintenance infusion after an initial bolus is necessary to ensure adequate anticoagulation during PCI.  \r\n$CTA\r\n\r\n[Letter sent to healthcare professionals in October 2007](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON2032914)\r\n\r\n[summary of product characteristics for Angiox▼](http://www.medicines.org.uk/EMC/medicine/16741/SPC/Angiox+250mg+powder+for+concentrate+for+solution+for+injection+or+infusion/)\r\n\r\nArticle citation: Drug Safety Update Jan 2008; Vol 1 Issue 6: 7\r\n"}],"max_cache_time":10},"routes":[{"path":"/drug-safety-update/bivalirudin-risks-associated-with-incorrect-dose","type":"exact"}],"redirects":[],"publishing_app":"specialist-publisher","rendering_app":"government-frontend","need_ids":[],"phase":"live","analytics_identifier":null,"document_type":"drug_safety_update","schema_name":"specialist_document","first_published_at":"2016-02-29T09:24:10Z","base_path":"/drug-safety-update/bivalirudin-risks-associated-with-incorrect-dose","description":"Incorrect dosage of bivalirudin in percutaneous coronary intervention can lead to major adverse cardiac events. ","content_id":"0fd6600c-cb68-4dd1-a274-0b419ab550e1","locale":"en","expanded_links":{"organisations":[{"analytics_identifier":"EA63","api_path":"/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency","base_path":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","description":null,"document_type":"organisation","locale":"en","public_updated_at":"2015-06-29T14:33:29Z","schema_name":"placeholder","title":"Medicines and Healthcare products Regulatory Agency","withdrawn":false,"details":{"brand":"department-of-health","logo":{"formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","crest":"single-identity"}},"links":{}}],"finder":[{"analytics_identifier":null,"api_path":"/api/content/drug-safety-update","base_path":"/drug-safety-update","content_id":"602be505-4cf4-4f8c-8bfc-7bc4b63a7f47","description":"Find drug safety updates issued by MHRA","document_type":"finder","locale":"en","public_updated_at":"2017-03-30T10:34:00Z","schema_name":"finder","title":"Drug Safety Update","withdrawn":false,"details":{"document_noun":"update","filter":{"document_type":"drug_safety_update"},"format_name":"Drug Safety Update","show_summaries":true,"facets":[{"key":"therapeutic_area","name":"Therapeutic area","type":"text","preposition":"about","display_as_result_metadata":true,"filterable":true,"allowed_values":[{"label":"Anaesthesia and intensive care","value":"anaesthesia-intensive-care"},{"label":"Cancer","value":"cancer"},{"label":"Cardiovascular disease and lipidology","value":"cardiovascular-disease-lipidology"},{"label":"Dentistry","value":"dentistry"},{"label":"Dermatology","value":"dermatology"},{"label":"Ear, nose and throat","value":"ear-nose-throat"},{"label":"Endocrinology, diabetology and metabolism","value":"endocrinology-diabetology-metabolism"},{"label":"GI, hepatology and pancreatic disorders","value":"gi-hepatology-pancreatic-disorders"},{"label":"Haematology","value":"haematology"},{"label":"Immunology and vaccination","value":"immunology-vaccination"},{"label":"Immunosuppression and transplantation","value":"immunosuppression-transplantation"},{"label":"Infectious disease","value":"infectious-disease"},{"label":"Neurology","value":"neurology"},{"label":"Nutrition and dietetics","value":"nutrition-dietetics"},{"label":"Obstetrics, gynaecology and fertility","value":"obstetrics-gynaecology-fertility"},{"label":"Ophthalmology","value":"ophthalmology"},{"label":"Paediatrics and neonatology","value":"paediatrics-neonatology"},{"label":"Pain management and palliation","value":"pain-management-palliation"},{"label":"Psychiatry","value":"psychiatry"},{"label":"Radiology and imaging","value":"radiology-imaging"},{"label":"Respiratory disease and allergy","value":"respiratory-disease-allergy"},{"label":"Rheumatology","value":"rheumatology"},{"label":"Urology and nephrology","value":"urology-nephrology"}]},{"key":"first_published_at","name":"Published","short_name":"Published","type":"date","preposition":"published","display_as_result_metadata":true,"filterable":true}],"default_documents_per_page":50},"links":{}}],"available_translations":[{"title":"Bivalirudin: risks associated with incorrect dose","public_updated_at":"2014-12-11T14:24:31Z","analytics_identifier":null,"document_type":"drug_safety_update","schema_name":"specialist_document","base_path":"/drug-safety-update/bivalirudin-risks-associated-with-incorrect-dose","description":"Incorrect dosage of bivalirudin in percutaneous coronary intervention can lead to major adverse cardiac events. ","api_path":"/api/content/drug-safety-update/bivalirudin-risks-associated-with-incorrect-dose","withdrawn":false,"content_id":"0fd6600c-cb68-4dd1-a274-0b419ab550e1","locale":"en"}]},"format":"specialist_document","navigation_document_supertype":"other","user_journey_document_supertype":"thing","email_document_supertype":"other","government_document_supertype":"other","payload_version":0}